Literature DB >> 29258126

Heart and Mitochondria: Pathophysiology and Implications for Cardiac Surgeons.

Bernd Niemann1, Michael Schwarzer2, Susanne Rohrbach3.   

Abstract

Excluding the heart from systemic circulation during cardiac surgery renders the myocardium ischemic, resulting in cardiac damage. In addition, another hit to the myocardium will occur upon restoration of blood flow, in the reperfusion phase. Experimental data from animal models have revealed that loss of cardiac metabolic flexibility and mitochondrial dysfunctions contributes to contractile impairment in hypertrophied, failing, obese, and diabetic hearts. Such diseased hearts are prone to myocardial ischemia-reperfusion (I/R) injury. Although analyses in human cardiac samples are not as comprehensive as animal data, similar disease-associated metabolic and mitochondrial changes exist. Considering increasing age and comorbidities in patients nowadays, it is not surprising that I/R injuries remain a major cause of morbidity and mortality after cardiac surgery. Mitochondria have emerged as critical targets but also key regulators of myocardial I/R injury, and the extent of mitochondrial damage is a major determinant of myocardial I/R injury. Although cardioprotective mechanisms are diverse, many come together and involve steps at the point of mitochondria. We will, therefore, provide a description of mitochondrial alterations observed in various cardiac disease states and discuss the current experimental knowledge of the role of mitochondria in I/R and of potential protective mechanisms against myocardial I/R injury involving mitochondria. Within this review, we will focus on the protection against I/R injury conferred by caloric restriction (CR) and by ischemic conditioning. Further research is needed to establish whether strategies targeting mitochondria, which have been proposed from preclinical studies, could be translated into cardioprotective therapies against I/R injury in patients. Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2017        PMID: 29258126     DOI: 10.1055/s-0037-1615263

Source DB:  PubMed          Journal:  Thorac Cardiovasc Surg        ISSN: 0171-6425            Impact factor:   1.827


  9 in total

Review 1.  Mitochondrial quality control in cardiac cells: Mechanisms and role in cardiac cell injury and disease.

Authors:  Farzaneh G Tahrir; Dianne Langford; Shohreh Amini; Taha Mohseni Ahooyi; Kamel Khalili
Journal:  J Cell Physiol       Date:  2018-11-11       Impact factor: 6.384

2.  The gender-specific expression of neuropeptide Y and neuropeptide Y receptors in human atrial tissue during cardiopulmonary bypass surgery.

Authors:  Fei Meng; Jie Han; Jiangang Wang; Haibo Zhang; Chunlei Xu; Xu Meng
Journal:  J Thorac Dis       Date:  2018-12       Impact factor: 2.895

3.  Mitochondrial implications in human pregnancies with intrauterine growth restriction and associated cardiac remodelling.

Authors:  Mariona Guitart-Mampel; Diana L Juarez-Flores; Lina Youssef; Constanza Moren; Laura Garcia-Otero; Vicente Roca-Agujetas; Marc Catalan-Garcia; Ingrid Gonzalez-Casacuberta; Ester Tobias; José C Milisenda; Josep M Grau; Fàtima Crispi; Eduard Gratacos; Francesc Cardellach; Glòria Garrabou
Journal:  J Cell Mol Med       Date:  2019-04-02       Impact factor: 5.310

Review 4.  Evaluating Novel Targets of Ischemia Reperfusion Injury in Pig Models.

Authors:  Andrea Baehr; Nikolai Klymiuk; Christian Kupatt
Journal:  Int J Mol Sci       Date:  2019-09-25       Impact factor: 5.923

5.  Impact of PCSK9 on CTRP9-Induced Metabolic Effects in Adult Rat Cardiomyocytes.

Authors:  Susanne Rohrbach; Ling Li; Tatyana Novoyatleva; Bernd Niemann; Fabienne Knapp; Nicole Molenda; Rainer Schulz
Journal:  Front Physiol       Date:  2021-02-11       Impact factor: 4.566

Review 6.  Mitochondria as a therapeutic target for cardiac ischemia‑reperfusion injury (Review).

Authors:  Wenwen Marin; Dennis Marin; Xiang Ao; Ying Liu
Journal:  Int J Mol Med       Date:  2020-12-16       Impact factor: 4.101

Review 7.  Rhodiola rosea: A Therapeutic Candidate on Cardiovascular Diseases.

Authors:  Yingqing Chen; Minli Tang; Shuo Yuan; Shuang Fu; Yifei Li; You Li; Qi Wang; Yuying Cao; Liping Liu; Qinggao Zhang
Journal:  Oxid Med Cell Longev       Date:  2022-02-27       Impact factor: 6.543

8.  Hypoxia Acclimation Protects against Heart Failure Postacute Myocardial Infarction via Fundc1-Mediated Mitophagy.

Authors:  Qin Li; Yinghai Liu; Qingqing Huang; Xiaobo Yi; Fuen Qin; Zuling Zhong; Lu Lin; Haihong Yang; Gu Gong; Wei Wu
Journal:  Oxid Med Cell Longev       Date:  2022-04-05       Impact factor: 6.543

9.  Danqi Pill Protects Against Heart Failure Post-Acute Myocardial Infarction via HIF-1α/PGC-1α Mediated Glucose Metabolism Pathway.

Authors:  Qian Zhang; Dongqing Guo; Yuanyuan Wang; Xiaoping Wang; Qiyan Wang; Yan Wu; Chun Li; Wei Wang; Yong Wang
Journal:  Front Pharmacol       Date:  2020-04-21       Impact factor: 5.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.